Stockwatch: Biosimilars And Dividends Connect Earnings At Pfizer And Roche
Missing Estimates May Not Be The Biggest Issue In Earnings Season
With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.
